SSRIs, MAOIs, lithium, and tramadol all interact with psilocybin — some reduce the effect, some create genuine danger. Here's what the clinical literature shows, in plain English.
Most harm reduction guides for psilocybin spend a paragraph on drug interactions. Most clinical trial protocols spend several pages on them — and will exclude a participant from a trial entirely if they're on certain medications.
That gap in emphasis is the point of this article. Drug interactions with psilocybin range from "your experience will be blunted and disappointing" to "this combination carries real medical risk." Knowing which category a given combination falls into is basic harm reduction, and the information exists in published pharmacology literature — it just rarely gets translated out of academic language.
This article covers the main interactions documented in the research: what happens mechanically, how serious the risk is, and what the clinical guidance actually says.
Psilocybin is converted in the body to psilocin, which binds primarily to the 5-HT2A serotonin receptor in the brain. That receptor binding is what drives the perceptual and psychological effects. This matters for understanding drug interactions because several common medications work by altering the serotonin system — which means they can either amplify, block, or dangerously interfere with psilocybin's effects.
The key pharmacological reference here is Nichols (2004), published in Pharmacological Reviews, which remains the most cited overview of psychedelic pharmacology and is the basis for most subsequent clinical trial guidance.
The short answer: SSRIs and SNRIs generally blunt psilocybin's effects. The combination is not considered dangerous, but the experience will likely be significantly weaker than expected.
SSRIs (selective serotonin reuptake inhibitors — fluoxetine, sertraline, escitalopram, citalopram, paroxetine) and SNRIs (venlafaxine, duloxetine) work by blocking the reuptake of serotonin at synapses, which increases serotonin availability. Over time, this causes the brain to downregulate — reduce the density and sensitivity of — serotonin receptors, including 5-HT2A, the primary target of psilocybin.
The result: when psilocybin is taken by someone on a chronic SSRI, there are fewer functional 5-HT2A receptors for psilocybin to bind to. The perceptual and psychological effects are reduced or sometimes absent entirely. Multiple clinical surveys and case reports document this consistently. The 2021 Carhart-Harris et al. trial (NEJM, DOI 10.1056/NEJMoa2032994) specifically excluded patients currently on antidepressants for this reason — not because the combination is unsafe, but because it would confound the results.
What this means practically: If you're currently on an SSRI or SNRI, psilocybin's effects will be blunted. Some people on SSRIs report minimal to no effect from doses that would ordinarily produce a full experience. Stopping an SSRI to restore sensitivity requires tapering under medical supervision and is not something to do informally — SSRI discontinuation carries its own risks (discontinuation syndrome).
The dose risk: People on SSRIs sometimes compensate by increasing the psilocybin dose significantly to try to overcome the blunting effect. This creates a different risk profile — if the SSRI is reduced or discontinued, that larger dose will suddenly deliver its full effect. This is worth flagging explicitly.
The short answer: Combining psilocybin with monoamine oxidase inhibitors (MAOIs) significantly intensifies the experience and introduces real medical risk. This combination requires serious attention.
MAOIs (phenelzine, tranylcypromine, isocarboxazid — all prescription antidepressants) block the enzyme monoamine oxidase, which normally breaks down serotonin, dopamine, and other monoamines in the body. Psilocin is also metabolized in part by monoamine oxidase. When MAOIs block that enzyme, psilocin is not cleared from the system as quickly — it accumulates, and the effect is dramatically potentiated and extended.
The clinical concern here is serotonin syndrome — a dangerous condition caused by excess serotonin activity. Symptoms range from mild (agitation, increased heart rate, tremors) to severe (hyperthermia, seizures, rapid cardiovascular changes). In clinical contexts, serotonin syndrome is a medical emergency.
Note: Some harm reduction communities discuss using Syrian Rue (Peganum harmala), which contains MAOIs, deliberately with psilocybin for potentiation. This is a different context than accidental co-administration with prescription MAOIs, but the pharmacological risks are the same. Intentional MAOI + psilocybin combinations should be treated with the same caution.
The shroomDOSAGE calculator includes an MAOI flag that reduces the recommended dose by 50% as a minimum precaution — but the risk goes beyond dosing math. Anyone on a prescription MAOI should not combine it with psilocybin without explicit medical guidance.
The short answer: Lithium and psilocybin is a combination that appears disproportionately in adverse event reports. The risk is real enough that clinical trials exclude lithium users entirely.
Lithium is used as a mood stabilizer, primarily in bipolar disorder. The mechanism of its interaction with psilocybin is not fully understood, but the pattern in case literature is consistent: the combination appears to increase the risk of seizures and cardiac irregularities significantly above what either substance produces alone.
Multiple case reports document seizure onset in individuals who combined psilocybin or LSD (which works on the same receptor pathway) with lithium — in some cases at doses of psilocybin that would ordinarily produce no adverse events. Every major psilocybin clinical trial protocol we've reviewed (MAPS, Compass Pathways, Johns Hopkins, Imperial College) lists current lithium use as an absolute exclusion criterion.
This is one of the clearest "do not combine" signals in the psilocybin harm reduction literature. If you are on lithium, the clinical guidance is unambiguous: do not combine.
The short answer: Tramadol is an opioid pain medication that also inhibits serotonin reuptake, which gives it a serotonin syndrome risk when combined with serotonergic compounds including psilocybin.
The tramadol interaction operates via a similar pathway to MAOIs — excess serotonin activity — though the threshold for concern is lower than with prescription MAOIs. The combination is flagged in pharmacology literature as requiring caution. Clinical trials exclude tramadol users along with other serotonergic medications.
The short answer: Not well-studied, but the combination increases cardiovascular stress. Heart rate and blood pressure elevation from both substances compound. This is generally categorised as unwise rather than categorically dangerous in the harm reduction literature, but it is worth flagging.
Psilocybin alone produces mild heart rate and blood pressure increases. Stimulants do the same. The combination amplifies these effects, and at high doses of either substance the cardiovascular load is meaningful.
The short answer: Cannabis significantly intensifies psilocybin experiences, especially at the peak. This is the most common unexpected amplification in recreational contexts.
Cannabis and psilocybin interact via different receptor systems (CB1 vs 5-HT2A) but the psychological effects potentiate each other substantially. Many adverse event reports from recreational use involve cannabis being added at peak, producing an experience significantly more intense than the person anticipated or wanted.
The pharmacological mechanism is not fully characterised, but the anecdotal and survey literature on this is consistent and large. Cannabis before or during a psilocybin experience should be considered a dose multiplier. Harm reduction guidance: if you use cannabis, don't add it at the peak. If you do, treat it as a significant dose escalation.
The short answer: Alcohol is not considered a dangerous interaction but it is counterproductive. It is a CNS depressant; psilocybin is a serotonergic compound. The pharmacological profiles are different enough that there's no dangerous amplification, but alcohol tends to reduce the clarity of a psilocybin experience and increase nausea.
Clinical protocols uniformly ask participants to abstain from alcohol for 24–48 hours prior to a session. The practical guidance is straightforward: alcohol and psilocybin don't interact dangerously, but they don't go well together.
This section is worth separating because the context is different from recreational use.
There is active clinical research into whether SSRI tapering prior to psilocybin-assisted therapy is necessary, beneficial, or appropriate for patients being treated for depression. Some research suggests the SSRI blunting effect can be partially overcome with higher doses; other research is investigating whether the combination produces any clinical benefit despite blunting. This is an open question in the field.
The Carhart-Harris et al. 2021 NEJM trial compared psilocybin directly against escitalopram (an SSRI) for depression — they were separate arms, not combined. The study found psilocybin non-inferior to escitalopram on the primary outcome at six weeks. This is not a statement about combining the two; it is a comparison between them.
If you are exploring psilocybin for therapeutic purposes and are currently on an antidepressant, this is a conversation for a healthcare provider familiar with psilocybin pharmacology — not something to navigate informally.
| Medication / Substance | Interaction Type | Risk Level | Clinical Guidance |
|---|---|---|---|
| SSRIs / SNRIs | Blunts effect (5-HT2A downregulation) | Low (safety) / Medium (dose escalation risk) | Clinical trials exclude; effect significantly reduced |
| MAOIs (prescription) | Potentiates effect; serotonin syndrome risk | High | Do not combine without medical supervision |
| Lithium | Seizure and cardiac risk; mechanism unclear | High | Clinical trials exclude absolutely |
| Tramadol | Serotonin syndrome risk | Medium-High | Clinical trials exclude; use caution |
| Stimulants | Increased cardiovascular load | Medium | Unwise at high doses of either |
| Cannabis | Significant psychological potentiation | Low-Medium | Treat as dose amplifier |
| Alcohol | Counterproductive; not dangerous | Low | Abstain 24–48h prior per clinical protocols |
The MAOI flag in the calculator reduces the recommended gram weight by 50% — reflecting the potentiation effect of MAO inhibition on psilocin metabolism. This is a harm reduction floor, not a green light. If you are on a prescription MAOI, the 50% reduction does not adequately address the serotonin syndrome risk.
The calculator does not adjust for SSRI blunting. The effect is real but highly variable — it depends on the specific SSRI, dose, duration, and individual neurochemistry — and we don't have reliable enough data to model it accurately. If you're on an SSRI and calibrating a dose, the most useful guidance is to start at the lower end of your target tier and treat it as a first-time experience with that combination.
Pharmacology information in this article is sourced from peer-reviewed literature and clinical trial protocols. This is not medical advice. If you are on psychiatric medication, consult a healthcare provider before using psilocybin.
About the author
D.Spora — Research Desk
Every article on shroomDOSAGE starts with primary sources — clinical trials, published assay data, peer-reviewed pharmacology. We translate the findings into plain English so you can understand what the science actually says, without needing a medical degree. Sources are cited inline. Nothing here constitutes medical advice.
Your cart is empty.
Browse the catalogue to add items.